{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:53:56Z","timestamp":1791262436338,"version":"4.1.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the expression levels of estrogen receptor (ER) and progesterone receptor (PR) in endometrial carcinoma (EC) and their correlations with standardized clinicopathological parameters in a single-center surgical cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Retrospective clinical and pathological data of 78 EC patients receiving primary surgery at the Department of Obstetrics and Gynecology of Kiang Wu Hospital between Jan 2016 and Aug 2022 were collected. ER\/PR expression was quantified via immunohistochemistry (IHC) using the Allred scoring system. Dichotomous receptor positivity (Allred 0\u20132 negative\/3\u20138 positive) and continuous total Allred scores were analyzed separately. Fisher\u2019s exact test or \u03c7\u00b2 test was used for categorical comparison; Kruskal-Wallis H test with adjusted\n                      <jats:italic>post-hoc<\/jats:italic>\n                      pairwise tests and Wilcoxon rank-sum test were applied for ordinal Allred score data. Exact P values, test statistics and degrees of freedom were reported for all analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall cohort included 71 endometrioid carcinoma (EC) and 7 non-endometrioid carcinoma (NEC) cases. ER and PR positive rates were significantly higher in endometrioid lesions (97.2% and 94.4%) than non-endometrioid subtypes (57.1% for both, P\u00a0=\u00a00.018\/P\u00a0=\u00a00.018). Continuous Allred scores of ER and PR declined significantly with worsening tumor differentiation (all adjusted P&amp;lt;0.05). For FIGO staging, significantly reduced ER and PR Allred scores were observed in Stage II compared with Stage I. The single Stage-III case was reported descriptively and was not included in formal statistical testing. Patients with lymph node metastasis exhibited lower PR Allred scores (P\u00a0=\u00a00.021), while ER expression showed no statistically significant difference (P\u00a0=\u00a00.076). No significant associations were found between ER\/PR scores and depth of myometrial invasion or lymphovascular space invasion (LVSI) (all P&amp;gt;0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Reduced ER and PR expression correlates with poorer tumor differentiation and advanced FIGO stage in endometrioid endometrial carcinoma; PR loss is independently associated with lymph node metastasis. This study only identifies crude cross-sectional correlations without survival or multivariable adjustment data, so ER\/PR may merely serve as auxiliary morphological markers reflecting tumor aggressive potential, rather than standalone indicators for prognosis or individualized hormone therapy guidance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1939245","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:56Z","timestamp":1791260756000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Expression of estrogen receptor and progesterone receptor in endometrial cancer and their correlations with clinicopathological features"],"prefix":"10.3389","volume":"16","author":[{"given":"En Ping","family":"Li","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology","place":["Kiang Wu Hospital, Macau SAR, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology","place":["Kiang Wu Hospital, Macau SAR, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie Zhen","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pathology","place":["Kiang Wu Hospital, Macau SAR, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Ke","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology","place":["Kiang Wu Hospital, Macau SAR, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai Qi","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology","place":["Kiang Wu Hospital, Macau SAR, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.41943","article-title":"Estrogen receptor, progesterone receptor, and HER2 receptor markers in endometrial cancer","volume":"11","author":"Wang","year":"2020","journal-title":"J Cancer"},{"key":"B2","article-title":"Diagnostic value of immunohistochemical biomarkers for early endometrial cancer","volume":"16","author":"Yang","year":"2022","journal-title":"Chin J Mod Drug Appl"},{"key":"B3","first-page":"97","article-title":"Associations of estrogen receptor, progesterone receptor and proto-oncoprotein expression with clinicopathological features in endometrial cancer","volume":"45","author":"Wang","year":"2017","journal-title":"Chin Clin Doctors"},{"key":"B4","first-page":"1874","article-title":"Expression of ER\/PR in endometrial cancer and their correlations with clinical characteristics and prognosis","volume":"19","author":"Hou","year":"2021","journal-title":"Cancer Prog"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/11795549221103200","article-title":"Estrogen receptor - and progesterone receptor-positive thresholds in predicting the recurrence of early low-risk endometrial cancer","volume":"16","author":"Li","year":"2022","journal-title":"Clin Med Insights Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/01443615.2017.1328591","article-title":"Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer","volume":"38","author":"Tomica","year":"2018","journal-title":"J Obstet Gynaecol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2019.02.12","article-title":"Potential role for a panel of immunohistochemical markers in the management of endometrial carcinoma","volume":"53","author":"Salama","year":"2019","journal-title":"J Pathol Transl Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100498","DOI":"10.1016\/j.currproblcancer.2019.07.003","article-title":"Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis","volume":"44","author":"G\u00fclseren","year":"2020","journal-title":"Curr Probl Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12040790","article-title":"Quantitative measurement of progesterone receptor immunohistochemical expression to predict lymph node metastasis in endometrial cancer","volume":"12","author":"Hsiao","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S263219","article-title":"Researches on the correlation between estrogen and progesterone receptors expression and disease-free survival of endometrial cancer","volume":"12","author":"Ren","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101402","article-title":"Correlation between steroid receptor expression and response to progestational therapy in patients with atypical endometrial hyperplasia or cancer","volume":"53","author":"Zaiem","year":"2024","journal-title":"Gynecol Oncol Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.17331","article-title":"The effect of progestin therapy in advanced and recurrent endometrial cancer: a systematic review and meta-analysis","volume":"130","author":"van Weelden","year":"2023","journal-title":"BJOG"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16112084","article-title":"Hormone receptor expression and activity for different tumour locations in patients with advanced and recurrent endometrial carcinoma","volume":"16","author":"Luijten","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-01031-6","article-title":"Contemporary use of hormonal therapy in endometrial cancer: a literature review","volume":"23","author":"Kailasam","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ygyno.2024.10.028","article-title":"Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer","volume":"192","author":"Vrede","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2026.37.e61","article-title":"Combined ER\/PR co-positivity enhances prognostic stratification within molecular subtypes of endometrial cancer","volume":"37","author":"Han","year":"2026","journal-title":"J Gynecol Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.humpath.2020.12.003","article-title":"The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study","volume":"109","author":"van Weelden","year":"2021","journal-title":"Hum Pathol"},{"key":"B18","volume-title":"WHO Classification of Tumours of the Female Reproductive Organs","author":"Kurman","year":"2014"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.33545\/gynae.2021.v5.i5c.1032","article-title":"The application of endometrial sampler SAP-1 to screening of endometrial cancer in postmenopausal women: a diagnostic test study","volume":"5","author":"Hong","year":"2021","journal-title":"Int J Clin Obstet Gynaecol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12967-019-1814-6","article-title":"Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line","volume":"17","author":"Li","year":"2019","journal-title":"J Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2019.02.002","article-title":"Endometrial cancer: an overview of pathophysiology, management, and care","volume":"35","author":"Passarello","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"B22","article-title":"Combined immunohistochemical markers and clinicopathological factors for predicting recurrence and survival of different endometrial cancer subtypes","volume":"52","author":"Huang","year":"2021","journal-title":"J Sichuan Univ (Med Sci Ed)"},{"key":"B23","article-title":"Correlations of ER, PR, Ki-67 and C-erbB-2 expression with pathological features in endometrial cancer","volume":"32","author":"Zhang","year":"2017","journal-title":"J North Sichuan Med Coll"},{"key":"B24","article-title":"Expression of ER, PR, C-erbB-2 and Ki-67 in endometrial cancer and their correlations with clinicopathological features","volume":"18","author":"Chen","year":"2019","journal-title":"J Clin Exp Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1939245\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:57Z","timestamp":1791260757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1939245\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1939245"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1939245","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1939245"}}